Iovance Biotherapeutics to present clinical, preclinical data for TIL therapies

Iovance Biotherapeutics announced the publication of abstracts for poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte, TIL, therapies at the Society for Immunotherapy of Cancer’s, SITC, 38th Annual Meeting in San Diego, CA, November 1-5, 2023. An abstract on the four-year analysis of pooled Cohorts 2 and 4 of the C-144-01 trial reports the longest follow-up data on lifileucel treatment outcomes in the largest population of patients with anti-PD-1-refractory advanced melanoma treated with TIL therapy. As of the data cutoff date of June 16, 2023, median C-144-01 trial follow-up was 48.1 months in heavily pretreated patients with advanced melanoma. One-time lifileucel TIL therapy demonstrated durable efficacy with a four-year OS rate of 22.2%. The longest response was ongoing at 59.9 months. Treatment-emergent adverse events were consistent with known safety profiles of lymphodepletion and IL-2, and their incidence decreased over time. The four-year analysis further supports the use of lifileucel as a potential treatment option in these patients that is differentiated from other immunotherapies.